Harris Gerd-Marie Eskerud, Wood Mollie, Eberhard-Gran Malin, Lundqvist Christofer, Nordeng Hedvig
Pharmacoepidemiology & Drug Safety Research Group, School of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, P.O. Box. 1068, Blindern, 0316, Oslo, Norway.
Department of Child Health, National Institute of Public Health, Oslo, Norway.
BMC Pregnancy Childbirth. 2017 Jul 14;17(1):224. doi: 10.1186/s12884-017-1399-0.
Few studies have investigated the drug utilization patterns and factors predicting drug use in pregnant women with migraine. This longitudinal drug utilization study aimed to describe patterns of analgesic use in a sample of Norwegian pregnant women according to their migraine history, and to identify predictors for analgesic use among these women.
Pregnant women giving birth at Akershus University Hospital between 2008 and 2010 were recruited at ultrasound examination in gestational week 17. Data were collected by questionnaires in gestational weeks 17 and 32, and at 8 weeks postpartum, and linked to birth records. Women were grouped into four categories according to migraine history: no migraine history, previous migraine history, recent migraine history (within 1 year prior to pregnancy) and migraine in pregnancy. Patterns of use of analgesics were analyzed descriptively. Multivariable logistic regression was used to identify factors predicting analgesic use.
Out of 1981 women, 5.0% reported having migraine in pregnancy, 13.2% had a recent history of migraine, 11.5% had a previous history of migraine, and 68.8% reported no history of migraine. Analgesic use declined during pregnancy. Many women switched from triptans and non-steroidal anti-inflammatory drugs to paracetamol, which constituted most of the analgesic use. Factors associated with analgesic use included recent migraine history (OR 1.6, 95% CI 1.2-2.2), more severe headache intensity (OR 1.3, 95% CI 1.3-1.4), smoking (OR 1.9, 95% CI 1.1-3.3) and multiparity (OR 1.4, 95% CI 1.1-1.7).
Women with migraine stop or switch medications during pregnancy. Analgesic use in pregnancy is affected by migraine characteristics and intensity, and also by socio-demographic factors. Clinicians should bear this in mind when giving advice on adequate management of migraine in pregnancy and safe analgesic use.
很少有研究调查偏头痛孕妇的药物使用模式及预测药物使用的因素。这项纵向药物使用研究旨在根据挪威孕妇的偏头痛病史描述其镇痛药物使用模式,并确定这些女性中镇痛药物使用的预测因素。
选取2008年至2010年在阿克什胡斯大学医院分娩的孕妇,于孕17周超声检查时招募。在孕17周、32周及产后8周通过问卷调查收集数据,并与出生记录相联系。根据偏头痛病史将女性分为四类:无偏头痛病史、既往有偏头痛病史、近期偏头痛病史(妊娠前1年内)及妊娠期偏头痛。对镇痛药物的使用模式进行描述性分析。采用多变量逻辑回归确定预测镇痛药物使用的因素。
在1981名女性中,5.0%报告妊娠期有偏头痛,13.2%有近期偏头痛病史,11.5%有既往偏头痛病史,68.8%报告无偏头痛病史。妊娠期镇痛药物使用减少。许多女性从曲坦类药物和非甾体抗炎药改用对乙酰氨基酚,后者占镇痛药物使用的大部分。与镇痛药物使用相关的因素包括近期偏头痛病史(比值比1.6,95%置信区间1.2 - 2.2)、更严重的头痛强度(比值比1.3,95%置信区间1.3 - 1.4)、吸烟(比值比1.9,95%置信区间1.1 - 3.3)及多胎妊娠(比值比1.4,95%置信区间1.1 - 1.7)。
偏头痛女性在孕期会停止或更换药物。孕期镇痛药物的使用受偏头痛特征和强度以及社会人口学因素的影响。临床医生在就孕期偏头痛的适当管理和安全使用镇痛药物提供建议时应牢记这一点。